Company overview
Mirai Bio is an open end-to-end platform for genetic medicine development founded by Flagship Pioneering in 2021. The company uses machine intelligence-based algorithms to optimize delivery to specific tissues and cell types, design nucleic acid-based therapeutics, and streamline manufacturing processes. Mirai enables biotech partners to co-create fully optimized genetic medicines while outsourcing key development and manufacturing capabilities.
Genetic Medicine Development Platform is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include genetic medicine platform, gene therapy development, nucleic acid therapeutics, lipid nanoparticles, drug delivery optimization.
Structured facts
- Website
- https://www.miraibio.com
- Markets served
- United States & Americas
- Keywords
- genetic medicine platform, gene therapy development, nucleic acid therapeutics, lipid nanoparticles, drug delivery optimization
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What core capabilities does Mirai Bio's platform provide?
- Mirai's platform addresses three key limitations in genetic medicine development: delivery optimization to any tissue and cell type, cargo design optimization, and manufacturing facilitation. The platform uses proprietary data algorithms and machine intelligence trained on high-throughput in vivo testing data to accelerate genetic medicines toward clinical translation.
- How does Mirai Bio's business model work with partners?
- Mirai operates an open platform model where biotech and pharma partners co-create optimized genetic medicines using Mirai's capabilities. Partners can focus on payload discovery and development while outsourcing delivery, design, and manufacturing optimization to Mirai, reducing the need for in-house infrastructure.
- What types of genetic medicines can Mirai Bio support?
- Mirai's platform supports nucleic acid-based therapeutics across multiple modalities and therapeutic areas. The company has demonstrated expertise with lipid nanoparticles for liver delivery, eye delivery, immune cell targeting, and hematopoietic stem cell delivery in bone marrow.
- Does Mirai Bio have manufacturing partnerships?
- Yes, Mirai Bio partnered with Thermo Fisher Scientific, a major CDMO, to develop and manufacture gene therapies. This collaboration pairs Thermo Fisher's manufacturing capacity and global reach with Mirai's machine intelligence platform for tissue-targeted delivery optimization.
- What is Mirai Bio's funding and leadership?
- Founded by Flagship Pioneering in 2021, Mirai received an initial $50 million commitment from Flagship. The company is led by Geoffrey von Maltzahn, PhD as founding CEO, and Hari Pujar, PhD as founding president.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
